Nilotinib Approved in Europe for Subset of Pediatric CML

November 20, 2017 – The European Commission (EC) has approved nilotinib for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP), both in the frontline setting and for those with resistance or intolerance to prior therapy including imatinib. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, which was … (leggi tutto)